Get the Stockscreener App
226.05
0.50%
1.12
Pre-market:
235.28
9.23
+4.08%
Overview
News
Price History
Option Chain
Financials
Why RMD Down?
Discussions
Forecast
Stock Split
Dividend History
Resmed Inc stock is traded at $226.05, with a volume of 1.03M.
It is up +0.50% in the last 24 hours and down -10.61% over the past month.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
See More
Previous Close:
$224.93
Open:
$224.25
24h Volume:
1.03M
Relative Volume:
0.96
Market Cap:
$32.93B
Revenue:
$5.40B
Net Income/Loss:
$1.49B
P/E Ratio:
22.34
EPS:
10.1168
Net Cash Flow:
$1.78B
1W Performance:
+0.70%
1M Performance:
-10.61%
6M Performance:
-20.20%
1Y Performance:
+6.13%
1-Day Range:
$222.35
$228.23
1-Week Range:
$219.01
$228.23
52-Week Range:
$201.84
$293.81
Resmed Inc Stock (RMD) Company Profile
Name
Resmed Inc
Sector
Industry
Phone
(858) 746-2400
Address
9001 SPECTRUM CENTER BLVD., SAN DIEGO, CA
Compare RMD vs ISRG, BDX, ALC, MDLN
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RMD
Resmed Inc
|
226.05 | 32.93B | 5.40B | 1.49B | 1.78B | 10.12 |
ISRG
Intuitive Surgical Inc
|
452.95 | 160.87B | 10.06B | 2.88B | 2.49B | 7.876 |
BDX
Becton Dickinson Co
|
154.96 | 44.08B | 21.92B | 1.76B | 2.63B | 6.1223 |
ALC
Alcon Inc
|
74.67 | 36.40B | 10.40B | 980.00M | 1.61B | 1.9749 |
MDLN
Medline Inc
|
43.12 | 35.00B | 28.43B | 1.16B | 1.26B | 1.4457 |
Resmed Inc Stock (RMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-16-25 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Sep-18-25 | Initiated | Citigroup | Buy |
| Sep-02-25 | Upgrade | CLSA | Hold → Outperform |
| Jul-15-25 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Mar-19-25 | Initiated | Morgan Stanley | Overweight |
| Jan-16-25 | Initiated | Goldman | Buy |
| Jan-10-25 | Initiated | Piper Sandler | Neutral |
| Dec-13-24 | Initiated | Stifel | Hold |
| Sep-24-24 | Initiated | Robert W. Baird | Outperform |
| Sep-18-24 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Sep-04-24 | Downgrade | Needham | Buy → Hold |
| Jun-25-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Jun-24-24 | Downgrade | Citigroup | Buy → Neutral |
| Feb-06-24 | Resumed | KeyBanc Capital Markets | Overweight |
| Oct-27-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-12-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Oct-09-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-29-23 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-06-23 | Upgrade | Needham | Hold → Buy |
| Sep-05-23 | Downgrade | UBS | Buy → Neutral |
| Aug-01-23 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| May-23-23 | Initiated | UBS | Buy |
| Apr-14-23 | Initiated | Mizuho | Buy |
| Jan-17-23 | Upgrade | JP Morgan | Neutral → Overweight |
| Oct-28-22 | Downgrade | Citigroup | Buy → Neutral |
| Oct-20-22 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Sep-08-22 | Upgrade | Citigroup | Neutral → Buy |
| Aug-15-22 | Downgrade | CLSA | Buy → Outperform |
| Aug-12-22 | Downgrade | Citigroup | Buy → Neutral |
| Aug-12-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-12-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-06-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Apr-06-22 | Initiated | Wolfe Research | Outperform |
| Jan-31-22 | Upgrade | Citigroup | Neutral → Buy |
| Jan-31-22 | Upgrade | Goldman | Neutral → Buy |
| Jan-28-22 | Upgrade | RBC Capital Mkts | Underperform → Sector Perform |
| Jan-24-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-24-22 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-13-22 | Upgrade | CLSA | Outperform → Buy |
| Jan-13-22 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Dec-21-21 | Upgrade | KeyBanc Capital Markets | Sector Weight → Overweight |
| Dec-06-21 | Upgrade | Macquarie | Neutral → Outperform |
| Oct-22-21 | Upgrade | CLSA | Underperform → Outperform |
| Aug-02-21 | Downgrade | CLSA | Outperform → Sell |
| Aug-02-21 | Downgrade | Needham | Buy → Hold |
| Jul-28-21 | Upgrade | Jefferies | Underperform → Hold |
| Jul-26-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-14-21 | Initiated | RBC Capital Mkts | Underperform |
| Jun-28-21 | Downgrade | Citigroup | Buy → Neutral |
| Jun-22-21 | Upgrade | Macquarie | Neutral → Outperform |
| Jun-22-21 | Initiated | Robert W. Baird | Neutral |
| Jun-21-21 | Reiterated | Needham | Buy |
| Jun-16-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Jun-09-21 | Upgrade | CLSA | Sell → Outperform |
| May-21-21 | Upgrade | JP Morgan | Neutral → Overweight |
| May-11-21 | Upgrade | Citigroup | Neutral → Buy |
| Apr-30-21 | Downgrade | Citigroup | Buy → Neutral |
| Mar-16-21 | Upgrade | Needham | Hold → Buy |
| Nov-02-20 | Upgrade | UBS | Neutral → Buy |
| Oct-30-20 | Upgrade | JP Morgan | Underweight → Neutral |
| Oct-27-20 | Upgrade | BofA Securities | Underperform → Neutral |
| Aug-07-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-17-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| May-01-20 | Downgrade | JP Morgan | Neutral → Underweight |
| May-01-20 | Upgrade | Oppenheimer | Perform → Outperform |
| Feb-18-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-03-20 | Initiated | CLSA | Underperform |
| Jan-31-20 | Downgrade | UBS | Buy → Neutral |
| Jan-10-20 | Initiated | Oppenheimer | Perform |
| Nov-22-19 | Initiated | KeyBanc Capital Markets | Sector Weight |
| Jul-29-19 | Upgrade | UBS | Neutral → Buy |
| Jul-16-19 | Downgrade | UBS | Buy → Neutral |
| May-06-19 | Upgrade | UBS | Neutral → Buy |
| Apr-18-19 | Upgrade | JP Morgan | Underweight → Neutral |
| Jan-25-19 | Downgrade | Goldman | Buy → Neutral |
| Jan-25-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Oct-26-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jul-02-18 | Initiated | Goldman | Buy |
View All
Resmed Inc Stock (RMD) Latest News
ResMed CEO Michael Farrell Plans Additional Insider Sale Under Rule 144 - TipRanks
Affiliate plans sale of 4,991 RMD shares via Fidelity (NYSE: RMD) - Stock Titan
Robinhood Asset Management Boosts ResMed Stake - National Today
Sleep Apnea Devices Market to Reach Strong Growth Through 2033 - openPR.com
ResMed Adjusts CDI and Share Balances Amid Transfers, Equity Issuance and Buybacks - TipRanks
ResMed Director Peter Farrell Plans Further Insider Share Sale Under Rule 144 - TipRanks
4,837 Shares in ResMed Inc. $RMD Acquired by Runnymede Capital Advisors Inc. - MarketBeat
Wealth Enhancement Advisory Services LLC Has $1.66 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
Element Squared LLC Buys Shares of 6,067 ResMed Inc. $RMD - marketbeat.com
Aberdeen Group Reduces Stake in ResMed Inc. - National Today
Aberdeen Group plc Sells 37,737 Shares of ResMed Inc. $RMD - MarketBeat
ResMed Inc. (NYSE:RMD) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Insider Sell: Brett Sandercock Sells Shares of ResMed Inc (RMD) - GuruFocus
RESMED INC. R (RME.MU) Q1 FY2025 earnings call transcript - Yahoo Finance
Resmed CFO Sandercock sells $224k in stock By Investing.com - Investing.com South Africa
Resmed CFO Sandercock sells $224k in stock - Investing.com
ResMed (RMD) CFO Sandercock sells 1,000 shares in open market trade - Stock Titan
J. Safra Sarasin Holding AG Sells 10,794 Shares of ResMed Inc. $RMD - MarketBeat
Spire Wealth Management Cuts Stock Holdings in ResMed Inc. $RMD - MarketBeat
Insider Sell: Peter Farrell Sells 2,000 Shares of ResMed Inc (RM - GuruFocus
ResMed Inc. (RMD) stock price, news, quote and history - Yahoo Finance UK
ResMed Inc. (RMD.AX) stock price, news, quote and history - Yahoo Finance Singapore
Insider Selling: ResMed (NYSE:RMD) Director Sells 2,000 Shares of Stock - MarketBeat
ResMed Inc. (RMD) latest stock news and headlines - Yahoo Finance Singapore
Resmed director Farrell sells $450,000 in stock By Investing.com - Investing.com India
Resmed director Farrell sells $450,000 in stock - investing.com
Resmed Insider Sold Shares Worth $450,000, According to a Recent SEC Filing - marketscreener.com
ResMed (NYSE: RMD) director sells 2,000 shares under Rule 10b5-1 plan - Stock Titan
ResMed Inc. (RMD) Stock forecasts - Yahoo Finance UK
Peter C. Farrell (RMD) sells 6,000 shares via Rule 144 notices (NYSE: RMD) - Stock Titan
Resmed to Report Third Quarter Fiscal 2026 Earnings on April 30, 2026 - The Manila Times
Resmed to post quarterly results after market close on April 30 - Stock Titan
Affiliate proposes three 1,000-share sales for RMD (NYSE: RMD) — broker listed - Stock Titan
ResMed Inc. stock rises Tuesday, still underperforms market - MarketWatch
Is It Time To Revisit ResMed (RMD) After Recent Share Price Weakness? - Yahoo Finance
ResMed (RMD) Valuation Check After Recent Share Price Weakness - Sahm
ResMed back on the Buy List - intelligentinvestor.com.au
ResMed Earnings Preview: What to Expect - Yahoo Finance
SG Americas Securities LLC Cuts Stock Position in ResMed Inc. $RMD - MarketBeat
Eagleford Energy and ResMed Compared - National Today
ResMed Inc. Stock: Navigating Sleep Apnea Market Leadership Amid Demographic Tailwinds and Digital I - AD HOC NEWS
ResMed Inc. (RMD) Launches Global Sleep Institute at World Sleep Congress - MSN
RBC Capital Maintains ResMed Inc.Depositary Receipt (RSMDF) Outperform Recommendation - MSN
ResMed stock price forecast: technical weakness persists as RMD struggles below key moving averages - Traders Union
Vanguard (RMD) disaggregates holdings; reports zero ownership in ResMed - Stock Titan
Regatta Capital Group LLC Invests $2.51 Million in ResMed Inc. - nationaltoday.com
Regatta Capital Group LLC Takes $2.51 Million Position in ResMed Inc. $RMD - MarketBeat
ResMed & Netwealth: A Fresh Look at Valuation Trends - Kalkine Media
Dakota Wealth Management Has $8.18 Million Holdings in ResMed Inc. $RMD - MarketBeat
Assenagon Asset Management S.A. Has $19.43 Million Stock Holdings in ResMed Inc. $RMD - MarketBeat
ResMed Inc. stock outperforms market despite losses on the day - MarketWatch
Resmed Inc Stock (RMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.73%
0.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):